Citations

Showing 10 of 108162 citations.

Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes
Wright, Clinton B. , Auchus, Alexander P. , Lerner, Alan J. , Ambrosius, Walter T. , Ay, Hakan , Bates, Jeffrey T. , Chen, Jing , Meschia, James F. , Pancholi, Suchita , Rastogi, Anjay , Sweeney, Mary Ellen, Willard, James , Yee, Jerry , Oparil, Suzanne , Meschia, James F , Papademetriou, Vasilios

Mayo Clinic

Hypertension | February 15, 2021 | Volume: 77 | Issue: 4 | Pages: 1391-1398

10.1161/hypertensionaha.120.16027 | PMID 33583199 Get It

In the SPRINT (Systolic Blood Pressure Intervention Trial), the number of strokes did not differ significantly by treatment group. However, stroke subtypes have heterogeneous causes that could respond differently to intensive blood pressure control. SPRINT participants (N=9361) were randomized to target systolic blood pressures of <120 mm Hg (intensive treatment) compared with <140 mm Hg (standard treatment). We compared incident hemorrhage, cardiac embolism, large- and small-vessel infarctions across treatment arms. Participants randomized to the intensive arm had mean systolic blood pressures of 121.4 mm Hg in the intensive arm (N=4678) and 136.2 mm Hg in the standard arm (N=4683) at one year. Sixty-nine strokes occurred in the intensive arm and 78 in the standard arm when SPRINT was stopped. The breakdown of stroke subtypes across treatment arms included hemorrhagic (intensive treatment, n=6, standard treatment, n=7) and ischemic stroke subtypes (large artery atherosclerosis: intensive treatment n=11, standard treatment, n=13; cardiac embolism: intensive treatment n=11, standard treatment n=15; small artery occlusion: intensive treatment n=8, standard treatment n=8; other ischemic stroke: intensive treatment n=3, standard treatment n=1). Fewer strokes occurred among participants without prior cardiovascular disease in the intensive (n=43) than the standard arm (n=61), but the difference did not reach predefined statistical significance level of 0.05 ( P =0.09). The interaction between baseline cardiovascular risk factor status and treatment arm on stroke risk did not reach significance ( P =0.05). Similar numbers of stroke subtypes occurred in the intensive BP control and standard control arms of SPRINT.
Hemodynamics and Clinical Implications of Occult Left Ventricular Dysfunction in Adults Undergoing Ebstein Anomaly Repair
Egbe, Alexander C. , Miranda, William R. , Connolly, Heidi M. , Dearani, Joseph A.

Mayo Clinic

Circulation: Cardiovascular Imaging | February 15, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circimaging.120.011739 | PMID 33583197 Get It

Background: Left ventricular global longitudinal strain (LVGLS) can detect early phases of LV systolic dysfunction, but its application has not been studied in Ebstein anomaly. We hypothesized that LVGLS can detect early phases of LV systolic dysfunction and that patients with occult LV systolic dysfunction will have worse hemodynamics, end-organ dysfunction, and suboptimal postoperative LV reverse remodeling after tricuspid valve surgery in comparison to patients with normal LV systolic function. Methods: In this retrospective cohort study, 371 Ebstein patients that underwent tricuspid valve surgery were divided into 3 groups: normal LV systolic function (normal LVGLS and LV ejection fraction; n=244, 77%), occult LV systolic dysfunction (abnormal LVGLS with normal LV ejection fraction; n=44, 14%), and overt LV systolic dysfunction (abnormal LVGLS and LV ejection fraction; n=27, 9%). Results: Compared with the normal LV function group, the occult group had smaller LV volume and cardiac output (2.1±0.4 versus 2.9±0.6 L/min per m 2 , P <0.001), worse end-organ dysfunction (glomerular filtration rate, 78±14 versus 91±18 mL/min per 1.73 m 2 , P =0.01), and suboptimal postoperative LV reverse remodeling. Although both the occult and overt groups had a similar degree of end-organ dysfunction (glomerular filtration rate, 78±14 versus 82±16 mL/min per 1.73 m 2 , P =0.3), the occult group was less likely to be on heart failure therapy (48% versus 96%, P <0.001). Conclusions: Abnormal LVGLS was associated with suboptimal postoperative LV reverse remodeling. These data suggest that LVGLS can potentially be used for risk stratification and provides a foundation for further studies to determine whether optimal heart failure therapy or tricuspid valve intervention can improve outcomes for LV systolic dysfunction in patients with Ebstein anomaly.
Abstract PD13-02: Site of recurrence after neoadjuvant therapy: A multi-center pooled analysis
Shad, Sonal , Noordaa, Marieke van der, Croze, Diane De, Reyal, Fabien , Monte-Millán, Marı́a del , Gould, Rebekah , Valero, Vicente , Steenbruggen, Tessa G. , Seijen, Maartje van , Bartlett, John M.S. , Edge, Stephen B. , Provenzano, Elena , Graham, A , Mackintosh, Lorna, Fang, Fan, Schwensen, Kelsey, Hayward, Larry , Thomas, Jeremy , Cole, Kimberly, Veer, Laura van’t, Symmans, Fraser, Esserman, Laura, Noordaa, Marieke E. M. van der, Osdoit, Marie , Hamy, Anne‐Sophie , Laé, Marick , Martín, Miguel , López‐Tarruella, Sara , Boughey, Judy C. , Goetz, Matthew P. , Hoskin, Tanya L. , Sonke, Gabe S. , Wesseling, Jelle , Kim, Mi‐Ok , Abraham, Jean , Caldas, Carlos , Earl, Helena , Sammut, Stephen‐John , Cameron, David , Graham, Ashley, Hall, Peter S , Fang, Fan, Godwin, Andrew K. , Sharma, Priyanka , DeMichele, Angela , Dunn, Janet , Hiller, Louise , Pusztai, Lajos , Yau, Christina

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD13-02-PD13-02

10.1158/1538-7445.sabcs20-pd13-02 Get It

Abstract Background: Achieving a pathologic complete response (pCR) has been shown on the patient level to predict excellent long-term event-free survival outcomes. Residual cancer burden (RCB) quantifies the extent of residual disease for patients who did not achieve pCR. We have previously observed in the I-SPY 2 TRIAL that while metastatic events outside the central nervous system (CNS) were dramatically reduced in the setting of pCR, the incidence of CNS metastasis remained similar across RCB classes, raising the possibility that these CNS events may be independent of response in the breast. In this study, we evaluate the type and sites of recurrences by RCB in a large pooled dataset, which allows for analysis within subtype, to validate these findings. Methods: 5161 patients pooled across 12 institutions/trials with available RCB and event-free survival (EFS) data were included in this analysis. EFS was calculated as the interval between treatment initiation, and locoregional recurrence, distant recurrence or death from any cause; patients without event are censored at time of last follow-up. The median follow-up is 4.6 years. We summarized the EFS event type, further sub-dividing the distant recurrence events (DR) by their site of relapse (CNS-only, CNS and other sites, Non-CNS). We used a competing risk (Fine-Gray) model to assess which of these site-specific relapses differ between RCB classes and estimated the cumulative incidence of CNS-only and non-CNS events at 5 years. Analyses were performed across the entire study population and within HR/HER2 defined subtypes. Results: Among the 5161 subjects, there were 1164 EFS events, including 92 (7.9%) local recurrences (without distant recurrence and/or death) and 1072 distant recurrence-free survival (DRFS) events. Among the DRFS events, 158 patients died without a distant recurrence. 914 experienced distant recurrences, including 90 (9.8%) with CNS-only, 145 (15.9%) with CNS and other sites, 664 (72.6%) with non-CNS distant recurrence; 15 (1.6%) patients had missing recurrence site information. Table 1 summarizes the cumulative incidence of CNS-only and non-CNS recurrence at 5 years and the proportion of CNS-only recurrences among DR events by RCB class overall and within each HR/HER2 subtypes. The incidence of CNS-only recurrences was low and similar across RCB classes. In contrast, the incidence of non-CNS recurrences increases with increasing RCB. As a result, CNS-only recurrences are proportionally higher within the RCB-0 and RCB-I than in the RCB-II and RCB-III groups, largely because of the low DR event rate and relative low frequency of non-CNS recurrence events within the RCB-0 and RCB-I classes. Overall, 27% of the recurrences in the setting of pCR (RCB-0) are due to CNS-only recurrences.Conclusions: Consistent with previous studies, our large pooled analysis confirmed that CNS-only recurrences are uncommon but appear similar across RCB groups, independent of response, suggesting that the CNS is a treatment sanctuary site. In contrast, non-CNS recurrence rates increase as RCB increases. These findings suggest that inclusion of CNS-only recurrences as an outcome event may impact the association between neoadjuvant therapy response and long-term outcomes in the context of current therapies. Novel therapies that cross the blood brain barrier will be needed to impact CNS recurrence rates. Table 1: Cumulative Incidence of CNS Only and non-CNS Distant Recurrences at 5 years and proportion of CNS-only events among DR eventsRCB Class0IIIIIIpOverall (5161)N16766622017806Cum. Inc. CNS Only2%2%2%1%0.627Cum. Inc. Non-CNS3%6%16%27%&lt;0.001# CNS-Only / # DR events (%)26/96 (27%)14/74 (19%)39/443 (9%)11/301 (4%)HR-HER2- (1774)N770212590202Cum. Inc. CNS Only2%3%2%4%0.298Cum. Inc. Non-CNS4%11%19%42%&lt;0.001# CNS-Only / # DR events (%)13/50 (26%)6/32 (19%)13/148 (9%)8/111 (7%)HR-HER2+ (572)N3766710029Cum. Inc. CNS Only1%5%5%0%0.022Cum. Inc. Non-CNS2%5%18%38%&lt;0.001# CNS-Only / # DR events (%)4/17 (24%)3/10 (30%)6/31 (19%)0/13 (0%)HR+HER2+ (858)N31317229182Cum. Inc. CNS Only1%1%2%0%0.37Cum. Inc. Non-CNS2%3%15%26%&lt;0.001# CNS-Only / # DR events (%)3/10 (30%)2/16 (12%)7/68 (10%)0/29 (0%)HR+HER2- (1957)N2172111036493Cum. Inc. CNS Only3%2%1%0.2%0.087Cum. Inc. Non-CNS5%4%13%20%&lt;0.001# CNS-Only / # DR events (%)6/19 (32%)3/16 (19%)13/196 (7%)3/148 (2%) Citation Format: Sonal Shad, Marieke van der Noordaa, Marie Osdoit, Diane de Croze, Anne-Sophie Hamy, Marick Lae, Fabien Reyal, Miguel Martin, María Del Monte-Millán, Sara López-Tarruella, I-SPY 2 TRIAL Consortium, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Gabe Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, John Bartlett, Stephen Edge, Mi-Ok Kim, Jean Abraham, Carlos Caldas, Helena Earl, Elena Provenzano, Stephen-John Sammut, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fan Fang, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela DeMichele, Janet Dunn, Louise Hiller, Larry Hayward, Jeremy Thomas, Kimberly Cole, Lajos Pusztai, Laura Van't Veer, Fraser Symmans, Laura Esserman, Christina Yau. Site of recurrence after neoadjuvant therapy: A multi-center pooled analysis [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD13-02.
Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore
Noordaa, Marieke EM van der, Shad, Sonal , Steenbruggen, Tessa G. , Croze, Diane De, Reyal, Fabien , Monte-Millán, Marı́a del , Valero, Vincent, Seijen, Maartje van , Bartlett, John, Edge, S.B., Provenzano, Elena , Graham, Ashley , Mackintosh, Lorna, Fan, Fang , Schwensen, Kelsey, Hayward, Larry , Thomas, Jeremy , Cole, Kimberley, Veer, Laura van ‘t , Symmans, Fraser, Noordaa, Marieke E. M. van der, Yau, Christina , Osdoit, Marie , Hamy, Anne‐Sophie , Laé, Marick , Martín, Miguel , López‐Tarruella, Sara , Boughey, Judy C. , Goetz, Matthew Bidwell , Hoskin, Tanya L. , Gould, Rebecca, Sonke, Gabe S. , Wesseling, Jelle , Bartlett, John, Kim, Mi‐Ok , Abraham, Jean , Caldas, Carlos , Earl, Helena , Sammut, Stephen‐John , Cameron, David , Graham, Ashley, Hall, Peter S , Godwin, Andrew K. , Sharma, Priyanka , DeMichele, Angela , Dunn, Janet , Hiller, Louise , Pusztai, Lajos , Veer, Laura J. van’t , Esserman, Laura J.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: GS4-07-GS4-07

10.1158/1538-7445.sabcs20-gs4-07 Get It

Abstract Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer is associated with improved survival. Further assessment of the extent of residual disease, using the pathological anatomic American Joint Committee on Cancer staging method (ypStage) or the Residual Cancer Burden (RCB) method, have been shown to add prognostic information for patients with residual disease. Neo-Bioscore, an alternate system to classify response to NAC, includes clinical stage at diagnosis and biology and defines eight prognostic groups. The goal of this study was to compared three scoring systems (anatomic ypStage (7th ed), RCB Class and Neo-Bioscore) and assess whether RCB Class and Neo-Bioscore provide additional prognostic value in the context above anatomic ypStage, the most commonly used method for post-neoadjuvant residual disease assessment. Methods: Data from 5161 patients treated with NAC was pooled from 12 sites. Patients without clinical and pathological staging were excluded, as were patients with HER2+ breast cancer who did not receive neoadjuvant HER2-targeted therapy, leaving 3730 for analysis. PCR was defined as no residual invasive tumor in breast and nodes, i.e. RCB-0 or ypT0/Tis and ypN0. Patients with discordant pCR status by RCB Class vs ypStage (n=9) were excluded. Associations between each scoring system and event-free survival (EFS) were evaluated using the log rank test. EFS at 5 years was estimated using the Kaplan Meier method. Associations between Neo-Bioscore and EFS were assessed in the pCR group. For patients with residual disease, we assessed RCB and Neo-Bioscore within each ypStage. Analysis was performed overall and within subtype. Subgroups with &lt;5 patients were excluded from the survival analyses. Results: ypAJCC staging, RCB class and Neo-Bioscore were all associated with EFS in the overall population and within each subtype (log rank p&lt;0.0001). Of note, 13 patients with a Neo-Bioscore of 7 all recurred or died within 19 months of follow-up. Overall, 34% (1264/3721) of patients achieved a pCR. Their Neo-Bioscore ranges from 0-5, where 3% (37/1264) has a Neo-Bioscore of 5 despite achieving pCR. The Neo-Bioscore was not associated with EFS in case of a pCR, with EFS estimates at 5 years of 95%, 94%, 92%, 93%, 90% and 92% for Neo-Bioscores 0-5 respectively. As HR and HER2 status are components of the score, the range of Neo-Bioscore in the pCR group differs by subtype. However, similar to the overall analysis, the Neo-Bioscore was not prognostic within subtypes in case of pCR. Overall, among the patients who did not achieve pCR, both RCB class and Neo-Bioscore were associated with EFS within ypStages I, II and III. However, the ypStage within which RCB and Neo-Bioscore are prognostic is different for each subtype. RCB class was prognostic in ypStage I in both HR+ subtypes: patients with ypStage-I/RCB-I had significantly improved survival compared to patients with ypStage-I/RCB-II (5-year EFS: 100% vs 83% in HR+HER2- and 95% vs 77% in HR+HER2+). In contrast, for patients with triple negative breast cancer, RCB class was prognostic within ypStage II and III. Analysis by clinical stage and the components of the three systems that contribute most to prognosis will be presented. Conclusions: The degree of response to NAC adds important information to pCR versus residual disease. The Neo-Bioscore was not prognostic among patients with pCR, suggesting that clinical stage (including subtype and grade) adds little information in the setting of a pCR. In contrast, both RCB and Neo-Bioscore provide additional prognostic information to the conventional ypAJCC staging among non-pCR patients, suggesting that clinical stage, tumor biology as well as extent of residual disease all contribute to prognosis in the setting of residual disease after NAC. Citation Format: Marieke EM van der Noordaa, Christina Yau, Sonal Shad, Marie Osdoit, Tessa G Steenbruggen, Diane de Croze, Anne-Sophie Hamy, Marick Lae, Fabien Reyal, Maria Del Monte-Millán, Miguel Martin, Sara Lopez Tarruella, I-SPY 2 TRIAL Consortium, Judy C Boughey, Matthew Goetz, Tanya Hoskin, Rebecca Gould, Vincent Valero, Gabe Sonke, Maartje van Seijen, Jelle Wesseling, John Bartlett, Stephan Edge, Mi-Ok Kim, Jean Abraham, Carlos Caldas, Helena Earl, Elena Provenzano, Stephen-John Sammut, David Cameron, Ashley Graham, Peter Hall, Lorna MacKintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela DeMichele, Janet Dunn, Louise Hiller, Larry Hayward, Jeremy Thomas, Kimberley Cole, Lajos Pusztai, Laura van 't Veer, Fraser Symmans, Laura Esserman. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr GS4-07.
Clinical outcomes of patients with diabetes mellitus and acute ST-elevation myocardial infarction following fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis
Ullah, Waqas , Saleem, Sameer , Sattar, Yasar , Mukhtar, Maryam , Younas, Sundas, Pasha, Ahmed K. , Inayat, Asad , Sattar, Yasar , Mukhtar, Maryam , Alraies, M Chadi , Zahid, Salman , Fischman, David L.

Mayo Clinic

Expert Review of Cardiovascular Therapy | February 15, 2021 | Volume: 19 | Issue: 4 | Pages: 357-362

10.1080/14779072.2021.1888716 | PMID 33567924 Get It

Management of irritable bowel syndrome with diarrhea: focus on eluxadoline
Heidelbaugh, Joel J., Kuritzky, Louis , Lacy, Brian E. , Lacy, Brian, Jones, Jennifer R. A. , Lembo, Anthony

Mayo Clinic

Current Medical Research and Opinion | February 15, 2021 | Volume: 37 | Issue: 4 | Pages: 567-578

10.1080/03007995.2021.1888705 | PMID 33566707 Get It

Lumping and splitting: The need for precision medicine and “personomics” in endometrial cancer
Reyes-Baez, Fiorella E. , Garzon, Simone , Mariani, Andrea

Mayo Clinic

Journal of Gynecologic Oncology | February 14, 2021 | Volume: 32 | Issue: 2 | Pages: No page available

10.3802/jgo.2021.32.e38 | PMID 33650339 Get It

Expanding the phenotype, genotype and biochemical knowledge of ALG3‐CDG
Alsharhan, Hind , Daniel, Earnest James Paul , Friedman, Jennifer , Pivnick, Enikö K., Faqeih, Eissa , Liu, Pengfei , Engelhardt, Nicole , Keller, Kierstin , Chen, Jie , Mazzeo, Pamela A., Bamshad, Michael J. , Nickerson, Deborah A. , Raymond, Kimiyo , He, Miao , Edmondson, Andrew C. , Lam, Christina , Raymond, Kimiyo M, Lam, Christina , Edmondson, Andrew C , Engelhardt, Nicole M , Ng, Bobby G. , Alhashem, Amal Mohammed , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Journal of Inherited Metabolic Disease | February 14, 2021 | Volume: 44 | Issue: 4 | Pages: 987-1000

10.1002/jimd.12367 | PMID 33583022 Get It

AbstractCongenital disorders of glycosylation (CDGs) are a continuously expanding group of monogenic disorders of glycoprotein and glycolipid biosynthesis that cause multisystem diseases. Individuals with ALG3‐CDG frequently exhibit severe neurological involvement (epilepsy, microcephaly, and hypotonia), ocular anomalies, dysmorphic features, skeletal anomalies, and feeding difficulties. We present 10 unreported individuals diagnosed with ALG3‐CDG based on molecular and biochemical testing with 11 novel variants in ALG3, bringing the total to 40 reported individuals. In addition to the typical multisystem disease seen in ALG3‐CDG, we expand the symptomatology of ALG3‐CDG to now include endocrine abnormalities, neural tube defects, mild aortic root dilatation, immunodeficiency, and renal anomalies. N‐glycan analyses of these individuals showed combined deficiencies of hybrid glycans and glycan extension beyond Man5GlcNAc2 consistent with their truncated lipid‐linked precursor oligosaccharides. This spectrum of N‐glycan changes is unique to ALG3‐CDG. These expanded features of ALG3‐CDG facilitate diagnosis and suggest that optimal management should include baseline endocrine, renal, cardiac, and immunological evaluation at the time of diagnosis and with ongoing monitoring.
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy
Wudhikarn, Kitsada , Padrnos, Leslie , LaPlant, Betsy, Kumar, Shaji , Lacy, Martha Q. , Rajkumar, S. Vincent , Gertz, Morie A. , Mangaonkar, Abhishek A. , Shi, Chang‐Xin, Stewart, A. Keith , Patnaik, Mrinal M. , Dispenzieri, Angela , Lacy, Martha, Rajkumar, S Vincent , Gertz, Morie A , Mangaonkar, Abhishek A. , Gonsalves, Wilson , Patnaik, Mrinal , Lasho, Terra L. , Dispenzieri, Angela , Gonsalves, Wilson I. , Ketterling, Rhett P. , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | February 14, 2021 | Volume: 96 | Issue: 5 | Pages: No page available

10.1002/ajh.26125 | PMID 33580975 Get It

Cricopharyngeal Myotomy in Inclusion Body Myositis: Comparison of Endoscopic and Transcervical Approaches
McMillan, Ryan A. , Bayan, Semirra L. , Kasperbauer, Jan L. , Ekbom, Dale C. , Kasperbauer, Jan , Ekbom, Dale , McMillan, Ryan A , Bayan, Semirra , Bowen, Andrew J.

Mayo Clinic

The Laryngoscope | February 14, 2021 | Volume: 131 | Issue: 8 | Pages: No page available

10.1002/lary.29444 | PMID 33577720 Get It

ObjectiveInclusion body myositis (IBM) is a progressive inflammatory myopathy with dysphagia as a debilitating sequalae. Otolaryngologists are consulted for surgical candidacy when there are findings of cricopharyngeal dysfunction. We aim to compare transcervical cricopharyngeal myotomy (TCPM) versus endoscopic cricopharyngeal myotomy (ECPM) in the IBM population with particular focus on objective swallow study outcomes, complications, and recurrence rates.MethodsA retrospective cohort study was performed on IBM patients who underwent TCPM or ECPM (1981–2020) in the Department of Otolaryngology at a tertiary academic center with a high volume IBM referral base. Videofluoroscopic swallow studies, Eating Assessment Tool (EAT‐10), Reflux Symptom Index (RSI), and Functional Outcome Swallowing Scale (FOSS) were collected at preoperative and follow‐up visits. Baseline patient characteristics, intraoperative data, and postoperative course were recorded.ResultsForty‐one patients were identified (18 TCPM; 23 ECPM). There was no significant difference in the recurrence rates, complications, hospitalization length, operative time, or return to preoperative diet between approaches. For the 12 patients (11 ECPM; 1 TCPM) that had subjective swallow data, there was a statistically significant difference in the pre and postoperative scores for EAT‐10, RSI, and FOSS (P < .05). There was a statistically significant improvement in the degree of narrowing between pre and postoperative imaging for both approaches (P < .05).ConclusionBoth TCPM and ECPM are safe approaches for the management of dysphagia in patients with IBM with objective evidence of cricopharyngeal dysfunction. Cricopharyngeal myotomy is a durable technique that has demonstrated improved subjective and objective outcomes in this patient population.Level of Evidence3 Laryngoscope, 131:E2426–E2431, 2021